HOME >> BIOLOGY >> NEWS
Oncolytics Biotech Inc. proceeds to initiate US Phase II sarcoma clinical trial

CALGARY, AB, --- April 11, 2007 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced that subsequent to the regulatory review period for this submission, it is proceeding with a Phase II trial to evaluate the intravenous administration of REOLYSIN in patients with various sarcomas that have metastasized to the lung. The Principal Investigators are Dr. Glenn S. Kroog of the Montefiore Medical Center/Albert Einstein College of Medicine in the Bronx, New York, Dr. Laurence H. Baker of the University of Michigan Comprehensive Cancer Center in Ann Arbor, and Dr. Monica Mita of the Cancer Therapy and Research Center, Institute for Drug Development in San Antonio, Texas.

"This multi-centre, Phase II trial follows the successful completion of systemic administration trials with REOLYSIN in the U.K. and the U.S.," said Dr. Karl Mettinger, Chief Medical Officer of Oncolytics. "This trial is the second in a series of Phase II trials the Company has planned for this year, and represents yet another step forward in the Company's clinical development strategy for REOLYSIN. We are excited to expand our clinical program to specifically include patients with sarcomas."

The trial (REO 014) is a Phase II, open-label, single agent study whose primary objective is to measure tumour responses and duration of response, and to describe any evidence of antitumour activity of intravenous, multiple dose REOLYSIN in patients with bone and soft tissue sarcomas metastatic to the lung. REOLYSIN will be given intravenously to patients at a dose of 3x1010 TCID50 for five consecutive days. Patients may receive additional five-day cycles of therapy every four weeks for a maximum of eight cycles. Up to 52 patients will be enrolled in the study.


'"/>

Contact: Cathy Ward
cathy.ward@oncolytics.ca
403-251-3807
Oncolytics Biotech Inc.
11-Apr-2007


Page: 1

Related biology news :

1. Oncolytics Biotech Inc., research collaborators demonstrate reovirus/gemcitabine
2. Biotech breakthrough could end biodiesels glycerin glut
3. How the Biotech Revolution Is Changing the Way We Fight Disease
4. Rutgers: GM/GMO/Biotech crop containment strategy
5. Ronald Cape to receive 2007 Biotechnology Heritage Award
6. Biotechnology Study Center honors Joan V. Ruderman, Salvador Moncada and Charles N. Serhan
7. European Federation of Biotechnology and Elsevier announce launch of biotechnology journal
8. Advances in Optics for Biotechnology, Medicine and Surgery
9. Biolex reports potential for more potent, efficacious antibodies in Nature Biotechnology
10. Developing uses for sugar-cane bagasse: Biotechnology applied to the paper industry
11. Biotech cotton provides same yield with fewer pesticides

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/3/2020)... ... September 03, 2020 , ... Litmus Health , the ... assessment of the company’s security practices has been completed. The assessment deemed Litmus ... comprehensive evaluation reviewed Litmus’ processes and systems, assessing them to see whether they ...
(Date:8/23/2020)... ... August 21, 2020 , ... The August edition ... and is now available on the company’s global website. Crystallography Times—an electronic newsletter ... presenting current news and crystallographic research. , The latest issue of Crystallography ...
(Date:8/12/2020)... ... August 11, 2020 , ... Both ... NJ, have entered into license agreements with Housey Pharma’s HMI subsidiary to gain ... and J&J have annual Research and Development spending in excess of US $10 ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is now offering ... 50 million stem cells total, patients may choose which extremities they would like treated. ... joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is obtained from ...
(Date:7/31/2020)... ... July 29, 2020 , ... eSource has long been touted as the ... the history of eSource, the reasons it did not take off as quickly as ... source, the industry is moving towards capturing data electronically for clinical trials and then ...
(Date:7/18/2020)... ... July 16, 2020 , ... “We are thrilled to deliver ... “It’s the only technology of its kind on the market and we were pleased ... the protective capacity of traditional cultured ingredients, creating a natural way to extend the ...
(Date:7/10/2020)... ... 2020 , ... In most research using the zebrafish model, ... in zebrafish embryos, maintaining optical transparency to facilitate microscopic imaging. Over the past ... the zebrafish model to investigate the causes of leukaemia and its relationship with ...
Breaking Biology Technology:
Cached News: